Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3252700 | 0.85 | TSHR (0.50) | SMPD1ALDH1A1HPGDLMNA | |
| SCHEMBL12348389 | 0.83 | KMT2A (0.45) | KMT2AMEN1LMNA | |
| SCHEMBL5671821 | 0.80 | CA12 (0.42) | KMT2ASMPD1ALDH1A1MEN1HDAC3 | |
| SCHEMBL16302551 | 0.80 | CA12 (0.53) | ALDH1A1HPGDLMNAHDAC11 | |
| SCHEMBL10291099 | 0.78 | MAPT (0.49) | KMT2AALDH1A1MEN1HDAC3HDAC2 | |
| SCHEMBL2234242 | 0.75 | TSHR (0.51) | KMT2AALDH1A1MEN1MAOBCYP3A4 | |
| SCHEMBL3373445 | 0.73 | SMPD1 (0.71) | KMT2ASMPD1MAOB | |
| SCHEMBL22502336 | 0.73 | THRA (0.64) | KMT2ASMPD1MEN1MAOBHPGD | |
| SCHEMBL13098212 | 0.73 | ALOX5 (0.51) | KMT2ASMPD1ALDH1A1MEN1 | |
| SCHEMBL7738234 | 0.73 | MMP2 (0.68) | MMP2MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487109-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI (FR) | 2013-07-16 | — | — | US | claimed |
| EP-2176203-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI SA (FR) | 2011-08-10 | — | — | EP | claimed |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | claimed |
| JP-2010531821-A | — | — | 2010-09-30 | — | — | JP | claimed |
| EP-2176203-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | claimed |
| WO-2009003589-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | claimed |
| US-8487109-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI (FR) | 2013-07-16 | — | — | US | disclosed |
| US-8487109-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI (FR) | 2013-07-16 | — | — | US | disclosed |
| US-8487109-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI (FR) | 2013-07-16 | — | — | US | disclosed |
| EP-2176203-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI SA (FR) | 2011-08-10 | — | — | EP | disclosed |
| EP-2176203-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI SA (FR) | 2011-08-10 | — | — | EP | disclosed |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| EP-2176203-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009003589-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003589-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | TYR, ALK, TYRO3 | KMT2A 1588/4885MMP2 4731/4885MMP12 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.